国药集团宣布溢价收购 派林生物股价低开低走

Core Viewpoint - The acquisition of Pailin Biological by China National Pharmaceutical Group is expected to create a new competitive landscape in the blood products industry, despite the premium offered for the shares [1] Company Summary - Pailin Biological announced a share transfer agreement where China National Pharmaceutical Group will acquire 21.03% of its shares, totaling 200 million shares [1] - The transaction is valued at 4.699 billion yuan, with a transfer price of 23.51 yuan per share, representing a 28% premium over the closing price on September 9 [1] - Following the completion of this transaction, China National Pharmaceutical Group will become the controlling shareholder of Pailin Biological [1] Industry Summary - Pailin Biological specializes in the research, development, production, and sales of blood products [1] - Tian Tan Biological, a subsidiary of China National Pharmaceutical Group, also operates in the blood products sector, indicating potential competition between the two companies post-acquisition [1] - China National Pharmaceutical Group has committed to not expanding its other controlled enterprises into businesses that compete with Pailin Biological's main operations [1]